| Symbol | NIKA |
|---|---|
| Name | NIKA PHARMACEUTICALS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 89044 United States NV 2269 Merrimack Valley Avenue |
| Telephone | (702)-326-3615 |
| Fax | — |
| — | |
| Website | https://www.nikapharmaceuticals.com |
| Incorporation | US |
| Incorporated On | 2000 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Boladale Lawal & Co (Chartered Accountants);Velikov Accounting Services Ltd.; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001145604 |
| Description | Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, which specializes in the treatment of HIV/AIDS, Chronic Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which a strengthened cell immunity is of vital importance. NIKA specializes in the field of scientific research with the goal of creating and developing new drugs and dietary supplements. At this moment in time, NIKAs intellectual property includes six drugs in injection form - two of which have successfully undergone clinical trials with good treatment results - four drugs in tablet form, and eleven dietary supplements. The goal of NIKA is to not only achieve corporate profits, but to also improve the quality of life of the population by providing better and easier access to life-saving medicinal drugs and useful dietary supplements. Additional info from OTC: |